Apogee grants 7,657 stock options at $85

Apogee Therapeutics, Inc. reported a routine equity compensation grant linked to director Tomas Kiselak and Fairmount Funds Management LLC.

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. reported a routine equity compensation grant linked to director Tomas Kiselak and Fairmount Funds Management LLC. A stock option was awarded representing the right to buy 7,657 shares of common stock at an exercise price of $85.00 per share.

The option vests on the one-year anniversary of the grant date, conditioned on Mr. Kiselak’s continued service. According to the footnotes, he holds the option for one or more investment vehicles managed by Fairmount, must deliver any net cash or stock to Fairmount, and therefore disclaims beneficial ownership, while Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.

Insider Trade Summary

Grant/Award: 7,657 shares

Grant/Award 1 txn

Insider Fairmount Funds Management LLC, Kiselak Tomas

Role Director | Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 contracts (Indirect, By: Tomas Kiselak)

Footnotes (2)

1. F1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
2. F2. Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Key Figures

Option size: 7,657 shares Exercise price: $85.00 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option size 7,657 shares Stock option covering common stock

Exercise price $85.00 per share Conversion or exercise price of option

Expiration date June 9, 2036 Option expiration

Shares underlying option 7,657 shares Underlying common stock

Shares after transaction 7,657 derivative units Total options held following grant

Key Terms

Stock Option (Right to Buy), grant/award acquisition, beneficial ownership, pecuniary interest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

beneficial ownership financial

"Mr. Kiselak therefore disclaims beneficial ownership of the option"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"Fairmount disclaims beneficial ownership ... except to the extent of its pecuniary interest"

continued service financial

"will vest on the one-year anniversary ... subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apogee Therapeutics (APGE) report in this Form 4?

Apogee Therapeutics reported a grant of a stock option covering 7,657 shares of common stock at an $85.00 exercise price. The option was awarded as compensation and not as an open-market purchase or sale of existing shares.

Who is associated with the new stock option grant at Apogee Therapeutics (APGE)?

The option is linked to director Tomas Kiselak, who holds it for one or more investment vehicles managed by Fairmount Funds Management LLC. Both Kiselak and Fairmount include footnote language limiting their beneficial ownership of the underlying common stock.

What are the key terms of the Apogee Therapeutics (APGE) stock option grant?

The stock option covers 7,657 shares of Apogee common stock with an $85.00 per share exercise price and expires on June 9, 2036. It vests on the one-year anniversary of the grant date, subject to continued service by the reporting person.

When does the new Apogee Therapeutics (APGE) stock option vest and expire?

The option will vest on the one-year anniversary of the June 9, 2026 grant date, provided the reporting person continues serving the issuer. It carries an expiration date of June 9, 2036, giving a long exercise window after vesting.

How do Fairmount Funds Management LLC and Tomas Kiselak treat beneficial ownership in this Apogee (APGE) filing?

The filing states Mr. Kiselak must turn over any net cash or stock from the option to Fairmount-managed funds, so he disclaims beneficial ownership. Fairmount likewise disclaims beneficial ownership of the securities except to the extent of its pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 08:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fairmount Funds Management LLC

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		(1)	06/09/2036	Common Stock	7,657	$0.00	7,657	I(2)	By: Tomas Kiselak

1. Name and Address of Reporting Person^*

Fairmount Funds Management LLC

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kiselak Tomas

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 2500

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

2. Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Remarks:

Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is a Managing Member of Fairmount.

	/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC	06/11/2026
	/s/ Tomas Kiselak	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)